China Reports Covid-19 Vaccine Expected To Be Ready This Year
This could be vaporware, designed to unsettle US and European researchers.
But given the propaganda value - and well as the attendant economic benefits of being the first to administer an effective Covid vaccine, it would be prudent to assume the Chinese labs with access to Wuhan data might be farther along than others. JL
Carlie Porterfield reports in Forbes:
A Chinese Covid-19 vaccine could be ready by the end of the year. A vaccine developed by two state-affiliated companies working in tandem
has the potential to be ready by the tail end of 2020 or by early 2021,
according to the state-owned Assets Supervision and Administration Commission. The Wuhan Institute of Biological Products and the Beijing Institute of
Biological Products have embarked on Phase II testing
and administered doses to2,000people during trials. The Beijing Institute of Biological Products will be able to manufacture between 100 million and120 millionvaccine doses per year
A Chinese Covid-19 vaccine could be ready by the end of the year, a government body has announced as nations race to be the first to come up with a defense against the virus that has infected nearly6 millionpeople and wrecked the world economy.
A Chinese-state controlled group announced the expect to distribute a Covid-19 vaccine by the end of... [+]
AFP VIA GETTY IMAGES
KEY FACTS
A vaccine developed by two state-affiliated companies working in tandem has the potential to be ready by the tail end of 2020 or by early 2021, according to a social mediapostmade Friday from the Chinese state-owned Assets Supervision and Administration Commission (SASAC).
The two firms, the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products, have embarked on Phase II testing for the vaccines and administered doses to more than2,000people during trials, according toReuters.
According to the SASAC, the Beijing Institute of Biological Products production line will be able to manufacture between 100 million and120 millionvaccine doses per year at full capacity.
There arefiveChinese-developed immunizations being tested on humans, more than any other country in the world.
China, where the Covid-19 virus is believed to haveoriginated, has its health organizations, regulators, research groups and even smaller private companies teaming up and workingovertimein a bid to come up with the world’s first effective Covid-19 vaccine.
While Chinese President Xi Jinping haspromisedto share any successful vaccine with other nations, vaccine manufacturing in China has been marred by production quality issues and safety scandals in the past, according toBloomberg.
KEY BACKGROUND
The Chinese expectation of a vaccine by the end of 2020 is aggressive compared to previous estimates that a vaccine could bea yearaway. But this week, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that a vaccine for Covid-19 could be ready as early asNovemberas the FDA fast-tracks vaccine trials. The Department of Health and Human Services has already inked contracts to order$100million worth of needles and syringes for a mass vaccination campaign. According to the World Health Organization, there were more than100potential Covid-19 vaccines in preclinical trials and 10 undergoinghuman trialsthis week.
TANGENT
The race for a vaccine heats up as tension between the U.S. and China escalates after nearly two years oftrade spats. U.S. President Donald TrumpattackedChina this week, claiming they instigated “the Wuhan virus” and then covered it up. Trump said Friday he will end the U.S. relationship with the WHO, which he has accused of being underChinese controland complicit in the coverup. He also announced he would implementnew sanctionsand visa restrictions for officials in China who had a role in Beijing’s newnational security billthat critics say will reduce Hong Kong’s autonomy from the mainland.
As a Partner and Co-Founder of Predictiv and PredictivAsia, Jon specializes in management performance and organizational effectiveness for both domestic and international clients. He is an editor and author whose works include Invisible Advantage: How Intangilbles are Driving Business Performance. Learn more...
0 comments:
Post a Comment